OptimizeRx (OPRX) 10-Q15 Aug 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 09, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Information [Line Items]
Entity Registrant Name	OptimizeRx Corporation
Entity Central Index Key	0001448431
Entity File Number	001-38543
Entity Tax Identification Number	26-1265381
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	260 Charles Street
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
Entity Phone Fax Numbers [Line Items]
City Area Code	248
Local Phone Number	651-6568
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	OPRX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		18,321,886

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 14,959	$ 13,852
Accounts receivable, net of allowance for credit losses of $371 and $480 at June 30, 2024 and December 31, 2023, respectively	24,521	36,253
Taxes receivable	1,842	1,036
Prepaid expenses and other	4,647	3,190
Total current assets	45,969	54,331
Property and equipment, net	171	149
Other assets
Goodwill	78,357	78,357
Other intangibles, net	14,470	15,198
Tradename and customer relationships, net	33,003	34,198
Operating lease right of use assets, net	472	573
Security deposits and other assets	434	568
Total other assets	126,736	128,894
TOTAL ASSETS	172,876	183,374
Current liabilities
Current portion of long-term debt	3,300	2,000
Accounts payable – trade	2,980	2,227
Accrued expenses	5,310	7,706
Revenue share payable	2,094	5,506
Taxes payable		49
Current portion of lease liabilities	219	222
Deferred revenue	1,053	172
Total current liabilities	14,956	17,882
Non-current liabilities
Long-term debt, net	32,296	34,231
Lease liabilities, net of current portion	271	371
Deferred tax liabilities, net	4,337	4,337
Total liabilities	51,860	56,821
Commitments and contingencies (See note 11)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at June 30, 2024 or December 31, 2023
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,061,907 and 19,899,679 shares issued at June 30, 2024 and December 31, 2023, respectively	20	20
Treasury stock, $0.001 par value, 1,741,397 shares held at June 30, 2024 and December 31, 2023	(2)	(2)
Additional paid-in-capital	196,164	190,793
Accumulated deficit	(75,166)	(64,258)
Total stockholders’ equity	121,016	126,553
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 172,876	$ 183,374

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for credit losses (in Dollars)	$ 371	$ 480
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, shares issued	20,061,907	19,899,679
Treasury stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Treasury stock, shares held	1,741,397	1,741,397

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net revenue	$ 18,812	$ 13,818	$ 38,502	$ 26,821
Cost of revenues, exclusive of depreciation and amortization presented separately below	7,108	5,993	14,595	11,563
Gross profit	11,704	7,825	23,907	15,258
Operating expenses
General and administrative expenses	14,380	12,209	30,545	26,208
Depreciation and amortization	1,073	465	2,140	929
Total operating expenses	15,453	12,674	32,685	27,137
Loss from operations	(3,749)	(4,849)	(8,778)	(11,879)
Other income (expense)
Interest expense	(1,528)		(3,074)
Other income	75		75
Interest income	106	721	125	1,386
Total other income (expense), net	(1,347)	721	(2,874)	1,386
Loss before provision for income taxes	(5,096)	(4,128)	(11,652)	(10,493)
Benefit (expense) from income taxes	1,088	(33)	744	(66)
Net loss	$ (4,008)	$ (4,161)	$ (10,908)	$ (10,559)
Weighted average number of shares outstanding – basic (in Shares)	18,257,879	16,992,100	18,213,992	17,043,493
Weighted average number of shares outstanding – diluted (in Shares)	18,257,879	16,992,100	18,213,992	17,043,493
Loss per share – basic (in Dollars per share)	$ (0.22)	$ (0.24)	$ (0.6)	$ (0.62)
Loss per share – diluted (in Dollars per share)	$ (0.22)	$ (0.24)	$ (0.6)	$ (0.62)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 18	$ (1)	$ 172,786	$ (46,692)	$ 126,111
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)
Stock based compensation expense Options			1,467		1,467
Stock based compensation expense Restricted stock			2,914		2,914
Issuance of common stock for options exercised (in Shares)	9,668
Issuance of common stock for options exercised			40		40
Issuance of common stock for restricted stock units vested			(171)		$ (171)
Issuance of common stock for restricted stock units vested (in Shares)	33,272				33,272
Net loss				(6,398)	$ (6,398)
Balance at Mar. 31, 2023	$ 18	$ (1)	177,036	(53,090)	123,963
Balance (in Shares) at Mar. 31, 2023	18,331,511	(1,214,398)
Balance at Dec. 31, 2022	$ 18	$ (1)	172,786	(46,692)	$ 126,111
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)
Issuance of common stock for restricted stock units vested (in Shares)					35,260
Repurchase of common stock					$ (7,522)
Net loss					(10,559)
Balance at Jun. 30, 2023	$ 18	$ (2)	173,049	(57,251)	115,815
Balance (in Shares) at Jun. 30, 2023	18,376,771	(1,741,397)
Balance at Mar. 31, 2023	$ 18	$ (1)	177,036	(53,090)	123,963
Balance (in Shares) at Mar. 31, 2023	18,331,511	(1,214,398)
Stock based compensation expense Options			1,655		1,655
Stock based compensation expense Restricted stock			1,848		1,848
Issuance of common stock for options exercised (in Shares)	10,000
Issuance of common stock for options exercised			105		105
Issuance of common stock for restricted stock units vested			(73)		(73)
Issuance of common stock for restricted stock units vested (in Shares)	35,260
Repurchase of common stock		$ (1)	(7,522)		(7,522)
Repurchase of common stock (in Shares)		(526,999)
Net loss				(4,161)	(4,161)
Balance at Jun. 30, 2023	$ 18	$ (2)	173,049	(57,251)	115,815
Balance (in Shares) at Jun. 30, 2023	18,376,771	(1,741,397)
Balance at Dec. 31, 2023	$ 20	$ (2)	190,793	(64,258)	126,553
Balance (in Shares) at Dec. 31, 2023	19,899,679	(1,741,397)
Stock based compensation expense Options			1,353		1,353
Stock based compensation expense Restricted stock			1,671		1,671
Issuance of common stock for options exercised (in Shares)	9,668
Issuance of common stock for options exercised
Issuance of common stock for restricted stock units vested			(140)		(140)
Issuance of common stock for restricted stock units vested (in Shares)	22,200
Net loss				(6,900)	(6,900)
Balance at Mar. 31, 2024	$ 20	$ (2)	193,677	(71,158)	122,537
Balance (in Shares) at Mar. 31, 2024	19,921,879	(1,741,397)
Balance at Dec. 31, 2023	$ 20	$ (2)	190,793	(64,258)	$ 126,553
Balance (in Shares) at Dec. 31, 2023	19,899,679	(1,741,397)
Issuance of common stock for options exercised (in Shares)					10,000
Issuance of common stock for restricted stock units vested (in Shares)					140,028
Net loss					$ (10,908)
Balance at Jun. 30, 2024	$ 20	$ (2)	196,164	(75,166)	121,016
Balance (in Shares) at Jun. 30, 2024	20,061,907	(1,741,397)
Balance at Mar. 31, 2024	$ 20	$ (2)	193,677	(71,158)	122,537
Balance (in Shares) at Mar. 31, 2024	19,921,879	(1,741,397)
Stock based compensation expense Options			1,149		1,149
Stock based compensation expense Restricted stock			1,753		1,753
Issuance of common stock for options exercised
Issuance of common stock for restricted stock units vested			(415)		(415)
Issuance of common stock for restricted stock units vested (in Shares)	140,028
Net loss				(4,008)	(4,008)
Balance at Jun. 30, 2024	$ 20	$ (2)	$ 196,164	$ (75,166)	$ 121,016
Balance (in Shares) at Jun. 30, 2024	20,061,907	(1,741,397)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
OPERATING ACTIVITIES:
Net loss	$ (10,908)	$ (10,559)
Adjustments to reconcile net loss to net cash provided by (used in) provided by operating activities:
Depreciation and amortization	2,140	929
Stock-based compensation	5,926	7,884
Bad debt expense	132	239
Amortization of debt issuance costs	365
Changes in:
Accounts receivable	11,600	3,635
Prepaid expenses and other assets	(1,457)	(1,772)
Accounts payable	752	(732)
Revenue share payable	(3,412)	(1,269)
Accrued expenses and other liabilities	(2,264)	(1,097)
Taxes payable	(855)
Deferred revenue	881	287
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	2,900	(2,455)
INVESTING ACTIVITIES:
Purchase of property and equipment	(77)	(49)
Purchases of held-to-maturity investments		(109,501)
Redemptions of held-to-maturity investments		112,501
Acquisition of intangible assets, including intellectual property rights		(3)
Capitalized software development costs	(161)	(1,274)
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	(238)	1,674
FINANCING ACTIVITIES:
Cash paid for employee withholding taxes related to the vesting of restricted stock units	(555)	(244)
Proceeds from exercise of stock options		145
Repurchase of common stock		(7,522)
Repayment of long-term debt	(1,000)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(1,555)	(7,621)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,107	(8,402)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	13,852	18,210
CASH AND CASH EQUIVALENTS - END OF PERIOD	14,959	9,808
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	2,710
Cash paid for income taxes	$ 110

Nature of Business and Basis of

Nature of Business and Basis of Presentation	6 Months Ended
Nature of Business and Basis of Presentation	Jun. 30, 2024
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the “Company”, “we”, “our”, or “us”). We are a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, as well as mass digital communications channels, OptimizeRx helps life sciences organizations engage and support their customers. We operate a single reporting segment and, accordingly, the consolidated statements of profit or loss provide this information and it is not presented separately here. The condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our financial position at June 30, 2024, and our results of operations, changes in stockholders’ equity, and cash flows for the six months ended June 30, 2024 and 2023, have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated balance sheet as of December 31, 2023, has been derived from the audited consolidated condensed balance sheet as of that date. Certain information and note disclosures, including a detailed discussion about the Company’s significant accounting policies, normally included in our annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with a reading of the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 15, 2024 (“Form 10-K”). The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. On October 24, 2023, the Company acquired 100% of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health (“Medicx Health”) - See Part II, Item 8. Financials Statements and Supplementary Data; Note 3 - Acquisitions in our Form 10-K for additional information regarding this transaction. The following presents the pro forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended Pro-forma consolidated statement of operations June 30, Revenue $ 22,408 $ 43,439 Net loss (6,076 ) (14,708 ) These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023, interest expense associated with the term loan and elimination of interest income on short-term investments that were used to fund the acquisition, During the year ended December 31, 2023, the Company disposed of its non-core Access business - See Part II, Item 8. Financials Statements and Supplementary Data; Note 7 - Goodwill and Intangible Assets in our Form 10-K for additional information regarding this transaction. A pro forma statement of operations for the three and six months ended June 30, 2024, is not presented for this transaction as the pro forma impacts were not material to the Company’s consolidated results. Revenue presented in the pro forma financial consolidated statement of operations data above includes $1,213 and $3,080, respectively related to the Access and other non-core solutions for which no revenue was recorded in the three and six months ended June 30, 2024, (see also the discussion under Net Revenues in Results of Operations for the three and six months ended June 30, 2024 in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations). Change in Accounting Estimate In accordance with its policy, the Company periodically reviews the stand-alone selling prices of its performance obligations under ASC 606 for use in allocating the contract prices. As a result, effective April 1, 2024, the Company updated the methodology for determining the value of program design and consulting services from the residual method to using an adjusted market assessment approach. The effect of this change in estimate was immaterial to the results for the three and six months ended June 30, 2024, but may become material in future periods. Fair Value of Financial Instruments Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using Level 3 inputs. The Company’s carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilities, approximate their fair values due to their short maturities.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
New Accounting Pronouncements	Jun. 30, 2024
New Accounting Pronouncements [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NOTE 2 – NEW ACCOUNTING PRONOUNCEMENTS In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	6 Months Ended
Cash, Cash Equivalents and Short-Term Investments	Jun. 30, 2024
Cash, Cash Equivalents and Short-Term Investments [Abstract]
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	NOTE 3 – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash equivalents include items almost as liquid as cash comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. We account for marketable equity securities in accordance with ASC 321-10, “Investments - Equity Securities”, as the shares have a readily determinable fair value quoted on the national stock exchange and are classified within Level 1 of the fair value hierarchy. At June 30, 2024 and December 31, 2023, we have recorded $8.1 million and none, respectively, of money market funds at cost.

Capitalized Software Costs

Capitalized Software Costs	6 Months Ended
Capitalized Software Costs	Jun. 30, 2024
Capitalized Software Costs [Abstract]
CAPITALIZED SOFTWARE COSTS	NOTE 4 – CAPITALIZED SOFTWARE COSTS The Company capitalizes certain development costs incurred in connection with software development for internal-use software platforms used in operations and for providing services to our customers. Costs incurred in the preliminary stages of development are expensed as incurred. Once software has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized internal use software development costs are included in intangible assets and are amortized on a straight-line basis over the estimated useful life of the software platforms and are included in depreciation and amortization within operating expenses in the consolidated statements of operations. Amortization of capitalized internal use software expense for the three and six months ended June 30, 2024 and 2023 was $71 and $141 and $48 and $95, respectively. The Company accumulates capitalizable costs related to current projects in a construction in process (“CIP”) software account, the balance of which was $393 and $696 at June 30, 2024 and December 31, 2023, respectively.

Revenues

Revenues	6 Months Ended
Revenues	Jun. 30, 2024
Revenues [Abstract]
REVENUES	NOTE 5 – REVENUES Under ASC 606, Revenue from Contracts with Customers Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of ePrescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers.The Company’s contracts are generally less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. Revenue is recognized at the point in time when the work product is delivered to the customer. The net contract balance for contracts in progress at June 30, 2024 and December 31, 2023, was $26,766 and $2,021, respectively. The outstanding performance obligations are expected to be satisfied during the year ended December 31, 2024. In certain circumstances, the Company will offer sales rebates to customers based on spend volume. Rebates are typically contracted based on a quarterly or annual spend amount based on a volume threshold or tiered model. At the beginning of the year, the rebate percentage is estimated based on input from the sales team and analysis of prior year sales. Thereafter, the open contract balance for the customer is assessed quarterly to ensure the estimated rebate percentage being used for the rebate accrual remains reasonable. The estimated amount of variable consideration will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the year ended 2023 and during the first half of 2024, there were two contracts with customers that included a rebate clause. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. In some instances, we also resell messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where we sell solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that we receive. In instances where we resell these messaging solutions and have all financial risk and significant operation input and risk, we record the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. 2024 2023 Balance January 1 $ 172 $ 164 Revenue recognized (3,228 ) (2,444 ) Amount collected 3,961 3,015 Balance March 31 $ 905 $ 735 Revenue recognized (1,853 ) (3,171 ) Amount collected 2,002 2,887 Balance June 30 $ 1,054 $ 451 Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, solution architect design, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. Three Months Ended Six Months Ended 2024 2023 2024 2023 Revenue recognized over time $ 17,769 $ 13,034 $ 34,694 $ 25,606 Revenue recognized at a point in time 1,043 784 3,809 1,215 Total Revenue $ 18,812 $ 13,818 $ 38,502 $ 26,821 Accounts receivable are reported at realizable value, net of allowances for credit losses, which is estimated and recorded in the period the related revenue is recorded. The Company does not seek collateral to secure its accounts receivable and amounts billed are generally due within a short period of time based on terms and conditions normal for our industry. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are written off when the Company’s collection efforts have been exhausted. The following is a summary of changes in the allowance for credit losses for the six months ended June 30,: 2024 2023 Balance at January 1, $ 239 $ 352 Bad debt expense 132 128 Write-offs — — Balance at March 31, $ 371 $ 480 Bad debt expense — 111 Write-offs — — Balance at June 30, $ 371 $ 591

Long-Term Debt

Long-Term Debt	6 Months Ended
Long-Term Debt	Jun. 30, 2024
Long-Term Debt [Abstract]
LONG-TERM DEBT	NOTE 6 – LONG-TERM DEBT Long-term debt, net June 30, December 31, Term loan, due in 2027 $ 37,290 $ 38,290 Less: current portion (3,300 ) (2,000 ) Less: unamortized issuance costs (1,694 ) (2,059 ) Long-term debt, net $ 32,296 $ 34,231 As of June 30, 2024, the Term loan bears interest at 14.1%, with an effective rate of 16.2%, including the impact of the amortization of debt issuance costs of $182 and $365 for the three and six months ended June 30, 2024, respectively. The Company was in full compliance with the financial covenants associated with the Term loan. The Term Loan is repayable in quarterly installments, beginning December 31, 2023, equivalent to 1.25% or $500,000, of the original principal amount, with the outstanding unpaid principal and all accrued but unpaid interest due and payable on the earlier of (i) the fourth anniversary of the closing date of the Term Loan or (ii) the date on which the Term Loan is declared due and payable pursuant to the terms of the Financing. In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00. Excess Cash Flow is defined in the Financing as Consolidated EBITDA for the previous fiscal year less scheduled principal and interest payments, capital expenditure, cash taxes and any cash expenses/gains added back to net income in the calculation of Consolidated EBITDA, adjusted for any increase/decrease in working capital during the fiscal year. Repayments due under the terms of the Term loan, including an estimate of the amount associated with the Excess Cash Flow calculation discussed above, for the remainder of the current and in each of the next three fiscal years are as follows: As of June 30, 2024 2024 (remainder) $ 1,000 2025 3,300 2026 2,000 2027 30,990 $ 37,290

Leases

Leases	6 Months Ended
Leases	Jun. 30, 2024
Leases [Abstract]
LEASES	NOTE 7 – LEASES We had operating leases with terms greater than 12 months for office space in four multi-tenant facilities, which are recorded as Operating lease right-of-use assets and Operating lease liabilities. For the three and six months ended June 30, 2024 and 2023, the Company’s lease cost consists of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations: Three months ended Six Months Ended 2024 2023 2024 2023 Operating lease cost $ 62 $ 25 $ 124 $ 49 Short-term lease cost — — 1 8 Total lease cost $ 62 $ 25 $ 125 $ 57 The table below presents the future minimum lease payments to be made under operating leases in each of the remainder of the current and next four fiscal years and thereafter: As of June 30, 2024 2024 (remainder) $ 132 2025 186 2026 113 2027 65 2028 45 Thereafter — Total 541 Less: discount 52 Total lease liabilities $ 489 The weighted average remaining lease term at June 30, 2024 for the operating lease is 2.8 years, and the weighted average discount rate used in calculating the operating lease asset and liability is 6.85%. Cash paid for amounts included in the measurement of lease liabilities was $109 and $45 for the six months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, payments on lease obligations were $127 and $49, respectively, and amortization on the right of use assets was $113 and $49, respectively.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2024
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY Preferred Stock The Company had 10,000,000 shares of preferred stock, $0.001 par value per share, authorized as of June 30, 2024. No Common Stock The Company had 166,666,667 shares of common stock, $0.001 par value per share, authorized as of June 30, 2024. There were 18,320,510 and 18,158,282 shares of common stock outstanding, net of shares held in treasury of 1,741,397 and 1,741,397 at June 30, 2024 and December 31, 2023, respectively. During each of the quarters ended March 31, 2024 and June 30, 2024, no no During the quarters ended March 31, 2024 and June 30, 2024, 22,200 and 140,028 shares of common stock, respectively, were issued in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. Some of the participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding taxes. Of the shares issued to participants during the six months ended June 30, 2024, a total of 48,281 shares, valued at $555,007, were surrendered and subsequently cancelled. During the quarters ended March 31, 2023 and June 30, 2023, the Company issued 9,668 and 10,000 shares of our common stock and received proceeds of $40 and $105, respectively, in connection with the exercise of options under our 2013 Incentive Plan. During the quarters ended March 31, 2023 and June 30, 2023, the Company issued 33,272 and 35,260 shares of common stock in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. 23,217 shares valued at $244 were surrendered in connection with the net withhold settlement method, and were subsequently cancelled. Treasury Stock During the quarter ended March 31, 2023, the Board authorized a share repurchase program, under which the Company could repurchase up to $15.0 million of its outstanding common stock. This stock repurchase authorization expired on March 12, 2024. During the quarter and months ended the Company did not repurchase any of its outstanding shares of common stock. During the quarter and months ended

Stock Based Compensation

Stock Based Compensation	6 Months Ended
Stock Based Compensation	Jun. 30, 2024
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	NOTE 9 – STOCK BASED COMPENSATION On June 5, 2024, at the 2024 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares of common stock available for awards under the 2021 Equity Incentive Plan by 1,950,000 shares for a total of 4,450,000 shares. Stock Options The compensation expense related to options for the six months ended June 30, 2024 and 2023 was $2,502 and $3,122, respectively. The fair value of these instruments was calculated using the Black-Scholes option pricing model. There is $5,031 of remaining expense related to unvested options to be recognized in the future over a weighted average period of 1.57 years. The total intrinsic value of outstanding options at June 30, 2024 was $214. During 2022, the Company granted certain performance based stock options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $8 in expense related to these options recorded during the three and six months ended June 30, 2024. Restricted Stock Units The Company recorded $3,424 and $4,762 in compensation expense related to restricted stock units for the six months ended June 30, 2024 and 2023, respectively. A total of $8,337 remains to be recognized at June 30, 2024 over a weighted average period of 1.52 years. During 2022, the Company granted certain performance based restricted stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $8 in expense related to these restricted stock units recorded during the three and six months ended June 30, 2024. The director’s compensation program calls for the grant of restricted stock units with a one year vesting period. There was $402 and $352 included in the compensation expense discussed above related to director’s compensation for the periods ended June 30, 2024 and 2023, respectively.

Loss Per Share

Loss Per Share	6 Months Ended
Loss Per Share	Jun. 30, 2024
Loss Per Share [Abstract]
LOSS PER SHARE	NOTE 10 – LOSS PER SHARE Basic earnings per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. The number of shares related to options and restricted stock units included in diluted EPS is based on the “Treasury Stock Method” prescribed in ASC 260-10, Earnings per Share The following table sets forth the computation of basic and diluted net loss per share. Three Months Ended Six Months Ended 2024 2023 2024 2023 Numerator Net loss $ (4,008 ) $ (4,161 ) $ (10,908 ) $ (10,559 ) Denominator Weighted average shares outstanding used in computing net loss per share Basic 18,257,879 16,992,100 18,213,992 17,043,493 Effect of dilutive stock options, warrants, and stock grants — — — — Diluted 18,257,879 16,992,100 18,213,992 17,043,493 Net loss per share Basic $ (0.22 ) $ (0.24 ) $ (0.60 ) $ (0.62 ) Diluted $ (0.22 ) $ (0.24 ) $ (0.60 ) $ (0.62 ) The number of common shares potentially issuable upon the exercise of certain options and the vesting of certain restricted stock units that were excluded from the diluted loss per common share calculation are reflected in the table below. Three Months Ended Six Months Ended Weighted average number of shares for the periods ended 2024 2023 2024 2023 Options 7,233 19,824 6,618 24,923 Unvested restricted stock unit awards 93,431 24,922 81,514 24,922 Total 100,664 44,746 88,132 49,845

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
Commitments and Contingent Liabilities	Jun. 30, 2024
Commitments and Contingent Liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 11 – COMMITMENTS AND CONTINGENT LIABILITIES Litigation From time to time, the Company may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us. Commitments From time to time, the Company enters into arrangements with partners to acquire minimum amounts of media, data or messaging capabilities. As of June 30, 2024, the Company had commitments for future minimum payments of $18.5 million that will be reflected in cost of revenues during the years from 2024 through 2028. Minimum payments are due in the remainder of 2024 and fiscal 2025, 2026, 2027 and 2028 in the amounts of $3.9 million, $8.5 million, $3.6 million, $2.4 million and $0.1 million, respectively.

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2024
Income Taxes [Abstract]
INCOME TAXES	NOTE 12 – INCOME TAXES The Company reported a benefit from income taxes of $1,088 and $744 for the three and six months ended June 30, 2024, representing an effective tax rate of 21.4% and 6.4%. The effective tax rate for the three and six months ended June 30, 2024 reflects the impact of certain permanent items, projected increases in our valuation allowance during the year and discrete items for the quarter related to stock based compensation. There was no As discussed in our annual report on Form 10-K for the year ended December 31, 2023, we had net operating loss carry-forwards for federal income tax purposes of approximately $16.7 million as of December 31, 2023.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS NONE

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,008)	$ (6,900)	$ (4,161)	$ (6,398)	$ (10,908)	$ (10,559)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Business and Basis _2

Nature of Business and Basis of Presentation (Tables)	6 Months Ended
Nature of Business and Basis of Presentation (Tables)	Jun. 30, 2024
Nature of Business and Basis of Presentation [Abstract]
Schedule of Pro-Forma Consolidated Statement of Operations	The following presents the pro forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended Pro-forma consolidated statement of operations June 30, Revenue $ 22,408 $ 43,439 Net loss (6,076 ) (14,708 )

Revenues (Tables)

Revenues (Tables)	6 Months Ended
Revenues (Tables)	Jun. 30, 2024
Revenues [Abstract]
Schedule of Deferred Revenue	The following is a summary of activity for the deferred revenue account for the six months ended June 30: 2024 2023 Balance January 1 $ 172 $ 164 Revenue recognized (3,228 ) (2,444 ) Amount collected 3,961 3,015 Balance March 31 $ 905 $ 735 Revenue recognized (1,853 ) (3,171 ) Amount collected 2,002 2,887 Balance June 30 $ 1,054 $ 451
Schedule of Revenue Recognition	A break down is set forth in the table below. Three Months Ended Six Months Ended 2024 2023 2024 2023 Revenue recognized over time $ 17,769 $ 13,034 $ 34,694 $ 25,606 Revenue recognized at a point in time 1,043 784 3,809 1,215 Total Revenue $ 18,812 $ 13,818 $ 38,502 $ 26,821
Schedule of the Allowance for Credit Losses	The following is a summary of changes in the allowance for credit losses for the six months ended June 30,: 2024 2023 Balance at January 1, $ 239 $ 352 Bad debt expense 132 128 Write-offs — — Balance at March 31, $ 371 $ 480 Bad debt expense — 111 Write-offs — — Balance at June 30, $ 371 $ 591

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
Long-Term Debt (Tables)	Jun. 30, 2024
Long-Term Debt [Abstract]
Schedule of Long-term Debt, Net	Long-term debt, net June 30, December 31, Term loan, due in 2027 $ 37,290 $ 38,290 Less: current portion (3,300 ) (2,000 ) Less: unamortized issuance costs (1,694 ) (2,059 ) Long-term debt, net $ 32,296 $ 34,231
Schedule of Repayments Due to Term loan	Repayments due under the terms of the Term loan, including an estimate of the amount associated with the Excess Cash Flow calculation discussed above, for the remainder of the current and in each of the next three fiscal years are as follows: As of June 30, 2024 2024 (remainder) $ 1,000 2025 3,300 2026 2,000 2027 30,990 $ 37,290

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 30, 2024
Leases [Abstract]
Schedule of Lease Cost	For the three and six months ended June 30, 2024 and 2023, the Company’s lease cost consists of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations: Three months ended Six Months Ended 2024 2023 2024 2023 Operating lease cost $ 62 $ 25 $ 124 $ 49 Short-term lease cost — — 1 8 Total lease cost $ 62 $ 25 $ 125 $ 57
Schedule of Future Minimum Lease Payments	The table below presents the future minimum lease payments to be made under operating leases in each of the remainder of the current and next four fiscal years and thereafter: As of June 30, 2024 2024 (remainder) $ 132 2025 186 2026 113 2027 65 2028 45 Thereafter — Total 541 Less: discount 52 Total lease liabilities $ 489

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
Loss Per Share (Tables)	Jun. 30, 2024
Loss Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share. Three Months Ended Six Months Ended 2024 2023 2024 2023 Numerator Net loss $ (4,008 ) $ (4,161 ) $ (10,908 ) $ (10,559 ) Denominator Weighted average shares outstanding used in computing net loss per share Basic 18,257,879 16,992,100 18,213,992 17,043,493 Effect of dilutive stock options, warrants, and stock grants — — — — Diluted 18,257,879 16,992,100 18,213,992 17,043,493 Net loss per share Basic $ (0.22 ) $ (0.24 ) $ (0.60 ) $ (0.62 ) Diluted $ (0.22 ) $ (0.24 ) $ (0.60 ) $ (0.62 )
Schedule of Vesting of Certain Restricted Stock Units	The number of common shares potentially issuable upon the exercise of certain options and the vesting of certain restricted stock units that were excluded from the diluted loss per common share calculation are reflected in the table below. Three Months Ended Six Months Ended Weighted average number of shares for the periods ended 2024 2023 2024 2023 Options 7,233 19,824 6,618 24,923 Unvested restricted stock unit awards 93,431 24,922 81,514 24,922 Total 100,664 44,746 88,132 49,845

Nature of Business and Basis _3

Nature of Business and Basis of Presentation (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Oct. 24, 2023
Nature of Business and Basis of Presentation [Abstract]
Number of US providers		2,000,000
Issued and outstanding share percentage			100%
Amount of net revenue	$ 1,213	$ 3,080

Nature of Business and Basis _4

Nature of Business and Basis of Presentation (Details) - Schedule of Pro-Forma Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Schedule of Pro-Forma Consolidated Statement of Operations [Abstract]
Revenue	$ 22,408	$ 43,439
Net loss	$ (6,076)	$ (14,708)

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Cash, Cash Equivalents and Short-Term Investments [Abstract]
Money market funds at cost	$ 8,100,000	$ 0

Capitalized Software Costs (Det

Capitalized Software Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Capitalized Software Costs [Line Items]
Amortization of software expense	$ 71	$ 48	$ 141	$ 95
Construction in process	$ 393		$ 393		$ 696

Revenues (Details)

Revenues (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Revenues (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Revenues [Abstract]
Accounts receivable	$ 4,134	$ 3,288
Net contract balance	26,766	2,021
Deferred revenue	$ 1,053	$ 172

Schedule of Deferred Revenue (D

Schedule of Deferred Revenue (Details) - Schedule of Deferred Revenue - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]
Deferred Revenue, Noncurrent	$ 1,054,000	$ 905,000	$ 451,000	$ 735,000	$ 172,000	$ 164,000
Deferred Revenue, Revenue Recognized	1,853,000	3,228,000	3,171,000	2,444,000
Deferred Revenue, Additions	$ 2,002,000	$ 3.961	$ 2,887,000	$ 3,015,000

Revenues (Details) - Schedule o

Revenues (Details) - Schedule of Revenue Recognition - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Revenue Recognition [Line Items]
Total Revenue	$ 18,812	$ 13,818	$ 38,502	$ 26,821
Revenue recognized over time [Member]
Schedule of Revenue Recognition [Line Items]
Total Revenue	17,769	13,034	34,694	25,606
Revenue recognized at a point in time [Member]
Schedule of Revenue Recognition [Line Items]
Total Revenue	$ 1,043	$ 784	$ 3,809	$ 1,215

Schedule of the Allowance for C

Schedule of the Allowance for Credit Losses (Details) - Schedule of the Allowance for Credit Losses - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 371	$ 371	$ 591	$ 480	$ 371	$ 591	$ 239	$ 352
Accounts Receivable, Credit Loss Expense (Reversal)		132	111	128	$ 132	$ 239
Accounts Receivable, Allowance for Credit Loss, Writeoff

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2024
Long-Term Debt [Line Items]
Term loan bears interest percentage		14.10%	14.10%
Effective rate			16.20%
Amortization of debt issuance costs		$ 182	$ 365
Percentage of repayable term loan	1.25%
Equivalent amount	$ 500,000
Leverage ratio, description			In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00.

Long-Term Debt (Details) - Sche

Long-Term Debt (Details) - Schedule of Long-term Debt, Net - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Long-term Debt, Net [Abstract]
Term loan, due in 2027	$ 37,290	$ 38,290
Less: current portion	(3,300)	(2,000)
Less: unamortized issuance costs	(1,694)	(2,059)
Long-term debt, net	$ 32,296	$ 34,231

Long-Term Debt (Details) - Sc_2

Long-Term Debt (Details) - Schedule of Repayments Due to Term loan $ in Thousands	Jun. 30, 2024 USD ($)
Schedule of Repayments Due to Term loan [Abstract]
2024 (remainder)	$ 1,000
2025	3,300
2026	2,000
2027	30,990
Total	$ 37,290

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	6 Months Ended
Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Weighted average remaining lease term	2 years 9 months 18 days
Weighted average discount rate	6.85%
Lease liabilities	$ 109	$ 45
Operating lease payment payments on lease obligation	127	49
Amortization right of use assets	$ 113	$ 49

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Cost - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Lease Cost [Abstract]
Operating lease cost	$ 62	$ 25	$ 124	$ 49
Short-term lease cost			1	8
Total lease cost	$ 62	$ 25	$ 125	$ 57

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Future Minimum Lease Payments $ in Thousands	Jun. 30, 2024 USD ($)
Schedule of Future Minimum Lease Payments [Abstract]
2024 (remainder)	$ 132
2025	186
2026	113
2027	65
2028	45
Thereafter
Total	541
Less: discount	52
Total lease liabilities	$ 489

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	10,000,000				10,000,000		10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001				$ 0.001		$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized	166,666,667				166,666,667		166,666,667
Common stock, par value (in Dollars per share)	$ 0.001				$ 0.001		$ 0.001
Common stock shares outstanding							18,158,282
Treasury common stock outstanding	1,741,397				1,741,397		1,741,397
Common stock were issued	20,061,907				20,061,907		19,899,679
Proceeds of common stock received amount (in Dollars)			$ 105	$ 40
Common stock shares issued				33,272	140,028	35,260
Restricted stock withholding shares				23,217	48,281
Restricted stock withholding value (in Dollars)					$ 555,007	$ 244
Common stock shares issued					10,000
Share repurchase program authorized amount (in Dollars)				$ 15,000
Share repurchase program authorized shares			526,999			526,999
Commission paid on repurchases (in Dollars)			$ 7,522			$ 7,522
Two Thousand Thirteen Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Proceeds of common stock received amount (in Dollars)					$ 105
2021 Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Proceeds of common stock received amount (in Dollars)
Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	10,000,000				10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001				$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized	166,666,667				166,666,667
Common stock, par value (in Dollars per share)	$ 0.001				$ 0.001
Common stock shares outstanding	18,320,510				18,320,510
Common stock were issued
Proceeds of common stock received amount (in Dollars)
Common stock shares issued	140,028	22,200	35,260	33,272
Common stock shares issued		9,668	10,000	9,668
Common Stock [Member] \| 2021 Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Proceeds of common stock received amount (in Dollars)		$ 40

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
Stock Based Compensation (Details) - USD ($) $ in Thousands	Jun. 05, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Stock Based Compensation [Line Items]
Total shares (in Shares)	4,450,000
Remaining expenses				$ 5,031
Expense remaining over a period				1 year 6 months 25 days
Total intrinsic value of outstanding options				$ 214
Compensation expense			$ 402	352
Restricted stock granted remains value			$ 8,337
Weighted average period			1 year 6 months 7 days
Vesting period			1 year
Stock Options [Member]
Stock Based Compensation [Line Items]
Compensation expense			$ 2,502	3,122
Stock expense		$ 8	8
Restricted Stock Units (RSUs) [Member]
Stock Based Compensation [Line Items]
Stock expense		$ 8	8
Compensation expense			$ 3,424	$ 4,762
2021 Incentive Plan [Member]
Stock Based Compensation [Line Items]
Total shares (in Shares)	1,950,000

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator
Net loss (in Dollars)	$ (4,008)	$ (6,900)	$ (4,161)	$ (6,398)	$ (10,908)	$ (10,559)
Weighted average shares outstanding used in computing net loss per share
Basic	18,257,879		16,992,100		18,213,992	17,043,493
Effect of dilutive stock options, warrants, and stock grants
Diluted	18,257,879		16,992,100		18,213,992	17,043,493
Net loss per share
Basic (in Dollars per share)	$ (0.22)		$ (0.24)		$ (0.6)	$ (0.62)
Diluted (in Dollars per share)	$ (0.22)		$ (0.24)		$ (0.6)	$ (0.62)

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of Vesting of Certain Restricted Stock Units - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			88,132	49,845
Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	100,664	44,746
Options [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			6,618	24,923
Options [Member] \| Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	7,233	19,824
Unvested Restricted Stock Unit Awards [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total			81,514	24,922
Unvested Restricted Stock Unit Awards [Member] \| Restricted Stock Units (RSUs) [Member]
Schedule of Vesting of Certain Restricted Stock Units [Line Items]
Total	93,431	24,922

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) $ in Millions	Jun. 30, 2024 USD ($)
Commitments and Contingent Liabilities [Abstract]
Total future minimum payment amount	$ 18.5
Minimum payment due two	3.9
Minimum payment due one	8.5
Minimum payment due three	3.6
Minimum payment due four	2.4
Minimum payment due five	$ 0.1

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income Taxes [Abstract]
Benefit from income taxes	$ (1,088)	$ 33	$ (744)	$ 66
Percentage of effective tax rate	21.40%		6.40%
Provision for or benefit from taxes
Federal income tax purposes					$ 16,700